Clinical Trials Browser

Has results × Breast Neoplasms × dalotuzumab × Clear all

NCT01605396 2019-03-25

MK-8669-064

Phase 2 Completed

80 enrolled 13 charts

Breast Neoplasms

NCT00759785 2018-08-15

MK-0646-013

Phase 1 Completed

48 enrolled 10 charts

Breast Neoplasms

NCT00903006 2015-02-02

Trial of Fulvestrant, MK-0646, and Dasatinib for Metastatic Hormone Receptor-Positive HER2-Negative Breast Cancer

Phase 1/2 Terminated

11 enrolled 6 charts

Breast Neoplasms